A single protein may be holding back CAR T cancer therapy

Researchers from Columbia University and University Hospital Tübingen have discovered a protein that appears to play a major role in weakening CAR T cells over time. By disabling the protein, known as NFIL3, the scientists found that these engineered immune cells remained active longer and were…

Continue Reading

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *